RADNOSTIX, INC.
radnostix.comRadnostix, Inc. (OTC: INIS) is a radioisotope manufacturing company that produces radioisotope-focused products for medical and industrial applications. Revenue comes from transactional product sales across five segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The company is headquartered in Idaho Falls, Idaho, was incorporated as a Texas corporation in 1995 (formerly International Isotopes Inc., renamed December 23, 2025), and operates manufacturing out of a single leased facility at 4137 Commerce Circle. Total revenue was $13 million in FY2025, the second-highest annual figure in company history. The Theranostics Products segment generated $6.8 million in FY2025 revenue, also the second-highest for that segment. Calibration & Reference Products accounted for approximately 33% of total revenue in FY2025 ($4,248,074), up from 25% ($3,519,216) in FY2024. The company holds the only FDA-approved generic sodium iodide I-131 ANDA manufactured in the United States, approved in February 2020. The company has never paid a cash dividend on its common stock.
Products & Services
Generic sodium iodide I-131 (ANDA approved February 2020, the only U.S.-manufactured FDA-approved generic); Theranostics Products in API and radiochemical form; Cobalt Products (including cobalt-60 sourced from the Advanced Test Reactor at Idaho National Laboratory); Calibration & Reference Products including PET-focused calibration sources; Medical Devices including radiosynthesis modules (Scintomics ATT line) and lung ventilation products (Swirler Radioaerosol System, Tru-Fit mouthpiece, Xenon System products acquired from AMICI, Inc., under development as of FY2025); Fluorine Products (no revenue since at least 2013).
Revenue Model
Transactional product sales across five segments. Theranostics Products (including generic sodium iodide I-131 sold to radiopharmacy customers, plus API and radiochemical forms) drove $6.8 million in FY2025 revenue. Calibration & Reference Products generated $4,248,074 in FY2025. Medical Devices segment revenue comes entirely from third-party product sales, including radiosynthesis modules distributed under a distribution and servicing agreement with Scintomics ATT (signed 2024). Fluorine Products recorded $0 in revenue in both FY2025 and FY2024.
Customers & Markets
Radiopharmacy customers who manufacture patient-specific capsules and sell to clinicians in the U.S. (sodium iodide I-131). End markets include thyroid disease treatment (hyperthyroidism, thyroid carcinoma), nuclear medicine calibration, theranostics, and medical imaging. Industrial customers for radiochemicals. The company ships sodium iodide I-131 to all 50 U.S. states and periodically to overseas locations.
Geographic Exposure
Primarily United States. Manufacturing operations in Idaho Falls, Idaho. TI Services subsidiary leases office space in Ohio. Sodium iodide I-131 shipped to all 50 U.S. states and periodically to some overseas locations. Conditional title held on 640 acres in Lea County, New Mexico (proposed de-conversion facility, on hold since 2013).
Financial Snapshot
Loading...
